Response to letter from Dr Oliviera in relation to our publication: A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin
Authors:
- 13 May 2019
- journal article
- letter
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 106, 347-348
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Evaluation of Uracil, Sodium Ascorbate, and Rosiglitazone as Promoters of Urinary Bladder Transitional Cell Carcinomas in Male Sprague-Dawley RatsToxicologic Pathology, 2018
- Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’Diabetes Therapy, 2015
- Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes MellitusDiabetes Therapy, 2014